Limula is pioneering advancements in the field of cell and gene therapy through its innovative manufacturing solutions. The company has developed a unique device that integrates a bioreactor and a centrifuge, allowing for on-demand and scalable production of cell therapies. This modular approach enables the sequencing of complex cell processing steps within a single container, significantly reducing the need for human intervention. Limula's technology is designed to be versatile, supporting various applications in both autologous and allogenic cell therapies, including T cells and hematopoietic stem cells. The system is user-friendly, combining operating units, consumables, and software to streamline the manufacturing process while minimizing hands-on time.

The core of Limula's offering lies in its proprietary bioreactor, which is engineered to facilitate both scale-down for process development and scale-up for commercial manufacturing. This innovative design addresses the critical challenge of producing personalized therapies at a reasonable cost, thereby enhancing global access to life-saving treatments. By focusing on automation and ease of use, Limula aims to revolutionize the manufacturing landscape of cell and gene therapies, making advanced medical solutions more accessible to patients worldwide.

Switzerland

Limula offers a unique technology supporting routine manufacturing of highly-personalised cell therapies. They provide a modular solution for on-demand cell and gene therapy manufacturing, addressing one of the biggest challenges in the field of medicine.

Limula

Company Details